Dr. Zhiqiang Wang 王志强
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of gastrointestinal tumors, including colorectal cancer, gastric cancer, esophageal cancer, and biliary and pancreatic tumors. Therapies include chemotherapy, targeted therapy, and immunotherapy.
Dr. Wang holds a medical doctorate and serves as Chief Physician and master’s supervisor.
Professional roles
- Vice Chair, Youth Committee of the Tumor Supportive Care Professional Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee of the Colorectal Cancer Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Youth Committee of the Tumor Targeted Therapy Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Youth Committee of the Medical Oncology Branch, Guangdong Medical Association
Name order: in Chinese the family name comes first (Wang Zhiqiang). Papers usually list the name as Zhiqiang Wang or Wang Z.
Selected publications
124 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Future Oncol, 2026 (first author): Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China. PubMed 42204923
- Oncologist, 2026 (senior author): Revised tumor burden score for prognostic stratification in metastatic colorectal cancer patients receiving immunotherapy: a retrospective study. PubMed 42103975
- Front Immunol, 2025 (senior author): Metastatic organ count stratifies survival in immunotherapy-treated metastatic colorectal cancer: a retrospective cohort study. PubMed 41445735
- Ther Adv Med Oncol, 2025 (senior author): Interim C-reactive protein levels predict the prognosis of patients with metastatic colorectal cancer receiving immunotherapy: a retrospective cohort study. PubMed 40761659
- Int Immunopharmacol, 2023 (senior author): Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy. PubMed 37536184
- Otolaryngol Head Neck Surg, 2022 (first author): Endoscopic Nasopharyngectomy Combined With Internal Carotid Artery Pretreatment for Recurrent Nasopharyngeal Carcinoma. PubMed 34182810
- Esophagus, 2022 (first author): Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. PubMed 34319435
- Invest New Drugs, 2021 (first author): Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study. PubMed 33070249
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion